[S-8] Inspire Veterinary Partners, Inc. Employee Benefit Plan Registration

Rhea-AI Filing Summary

Aimfinity Investment Corp. I (NASDAQ: AIMAU) filed its Form 10-Q for the quarter ended March 31 2025. The blank-check company remains in the pre-combination stage and is pursuing the previously announced merger with Docter Inc. Key developments during the quarter are outlined below.

Capital structure and liquidity

• Cash outside the Trust Account remained minimal at $4,895.
• Funds in the Trust Account fell to $13.67 million from $36.94 million at 31 Dec 2024 after the redemption of 1,996,522 Class A shares for $23.78 million.
• Ordinary shares subject to redemption declined to 1,116,476 (redemption value $12.25 per share).
• Working-capital deficit widened to $3.72 million (vs. $3.28 million year-end), driven by related-party loans (working-capital loan $1.32 million, extension loan $1.47 million).

Operating results

• Formation & operating costs: $277,251 (up 114% YoY).
• Interest income from the Trust Account: $342,182 (down 40% YoY).
• Net income: $64,931 vs. $438,864 in Q1-24. The decrease reflects lower interest income and higher professional fees.

Going-concern & extensions

• Management states that limited cash and a working-capital deficit “raise substantial doubt” about the company’s ability to continue as a going concern.
• The Charter was amended on 9 Jan 2025 to allow nine one-month extensions up to 28 Oct 2025; $1.47 million had been deposited into the Trust as of 31 Mar 2025 to secure extensions through 28 May 2025.

Business-combination progress

• The Merger Agreement with Docter Inc. (medical-device company) was amended on 29 Jan 2025 to introduce earn-out thresholds: 1.0 million shares for 30,000 device sales (FY25) and 1.5 million shares for 40,000 device sales (FY26).

Subsequent events

• April 2025: an additional $55,824 deposited for another monthly extension.
• April 8 2025: ~$1.5 million of promissory notes converted into 150,000 private units.
• May 27 2025: PubCo agreed to acquire Inkrock Holding Limited (real estate asset) by issuing 687,054 shares, assuming a $1.4 million mortgage.

Share counts

• Class A shares outstanding: 1,758,476 (includes shares still subject to redemption).
• Class B (founder) shares: 2,012,500.
• Public warrants: 8,542,000; Class 2 warrants: 1,802,499.

Outlook

The company must complete the Docter merger or another business combination by the final extended deadline (up to 28 Oct 2025) or liquidate. Completion depends on additional financing, shareholder support and timely SEC clearance.

Insights

SPAC Financial Analyst

TL;DR: Significant redemptions shrink trust to $13.7 m; going-concern risk intensifies, but merger talks advance with revised earn-outs.

From a financing perspective, Aimfinity has lost roughly two-thirds of its Trust capital since year-end due to the January redemption wave. With just $13.7 m remaining, any post-combination cash will be tight once fees and taxes are deducted. The working-capital deficit of $3.7 m, combined with the lack of cash outside the Trust, underscores the ‘substantial doubt’ language. Extension and working-capital loans, which now total $2.79 m and are convertible into private units, dilute founders but buy time.

The amended earn-out structure aligns Docter’s incentives with revenue (device-unit sales), potentially appeasing shareholders who worry about valuation. Nonetheless, the SPAC now needs PIPE or other external capital to ensure the merger closes with adequate cash.

Bottom line: Neutral-to-negative near term—trust erosion and going-concern risk offset the incremental progress on the deal.

Corporate Governance & Risk Specialist

TL;DR: Heavy reliance on related-party loans and insider asset purchase elevate governance and execution risks.

The SPAC’s survival currently depends on loans from the sponsor (working-capital and extension facilities totalling $2.79 m). While structurally common, these notes are convertible into additional private units, increasing insider influence post-merger. The subsequent acquisition of Inkrock Holding from the sponsor for shares, plus assumption of a $1.4 m mortgage, adds a conflicted-party layer that investors must vet.

Redemptions reduced public float and could simplify vote math, but they also lower the available capital for Docter’s growth. Combined with the going-concern warning, the risk-reward profile remains skewed toward downside until financing and regulatory hurdles are cleared.

As filed with the Securities and Exchange Commission on June 20, 2025.

Registration No. 333-                       

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

INSPIRE VETERINARY PARTNERS INC.

(Exact name of registrant as specified in its charter)

 

Nevada	 	85-4359258
(State or other jurisdiction of incorporation or organization)	 	(I.R.S. Employer Identification No.)

 

780 Lynhaven Parkway, Suite 400

Virginai Beach, VA 23452

(Address of Principal Executive Offices)

 

Inspire Veterinary Partners, Inc. 2022 Equity Incentive Plan

(Full title of the plan)

 

Mark E. Crone, Esq.

The Crone Law Group, P.C.

420 Lexington Avenue, Suite 2446

New York, NY 10170

(Name and address of agent for service)

 

757-734-5464

(Telephone number, including area code, of agent for service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

☐ Large accelerated filer	☐ Accelerated filer
☒ Non-accelerated filer	☒ Smaller reporting company
☒ Emerging growth company	 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement is being filed by Inspire Veterinary Partners, Inc., a Nevada corporation (the “Company”), in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”). The Company’s 2022 Equity Incentive Plan (the “2022 Plan”), which was adopted by the board of directors and approved by the shareholders of the Company on October 18, 2022, allows for issuances not to exceed 10% of the authorized shares of the Company. We are registering 10,000,000 shares of Class A common stock of the Company, par value $0.0001 per share, issuable pursuant to the 2022 Plan which represents 10% of the authorized shares of the Company at the time of this Registration Statement.

 

 

 

 

PART I

 

INFORMATION REQUIRED IN SECTION 10(a) PROSPECTUS

 

Item 1. Plan Information.*

 

Item 2. Registrant Information and Employee Plan Annual Information.*

 

Information required by Part I to be contained in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities Act of 1933, and Note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the Equity Incentive Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

 

1

 

 

PART II

 

Item 3. Incorporation of Documents by Reference.

 

The following documents filed by the Company with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

 

1. The registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 31, 2025 (File Number: 001-41792) (the “2024 Form 10-K”);

 

2. The registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 15, 2025;

 

3. All other reports filed by the registrant with the Commission pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Form 10-K (other than the portions of these documents not deemed to be filed); and

 

4. the description of the Class A common stock contained in the registrant’s registration statement on Form 8-A filed with the SEC on August 29, 2023, including any amendments or reports filed for the purposes of updating this description, including Exhibit 4.2 to the 2024 Form 10-K.; and

 

All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which de-registers all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents.

 

Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Item 4. Description of Securities.

 

Not Applicable

 

Item 5. Interests of Named Experts and Counsel.

 

No expert or counsel named in this prospectus as having prepared or certified any part of it or as having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the Common Stock was employed on a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in the Company or any of its parents or subsidiaries. Nor was any such person connected with the Company or any of its parents or subsidiaries as a promoter, managing or principal underwriter, voting trustee, director, officer, or employee.

 

Item 6. Indemnification of Directors and Officers.

 

Section 78.7502 of the Nevada Revised Statutes provides that a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he is not liable under Section 78.138 of the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation or he acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

 

II-1

 

 

Section 78.7502 further provides a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he is not liable under Section 78.138 of the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation or he acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper. To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any non-derivative proceeding or any derivative proceeding, or in defense of any claim, issue or matter therein, the corporation shall indemnify him or her against expenses, including attorneys’ fees, actually and reasonably incurred in connection with the defense. Further, Nevada law permits a Nevada corporation to purchase and maintain insurance or to make other financial arrangements on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him or her and liability and expenses incurred by him or her in his or her capacity as a director, officer, employee or agent, or arising out of his or her status as such, whether or not the corporation has the authority to indemnify him or her against such liability and expenses.

 

The amended and restated articles of incorporation and the amended and restated bylaws of the Company provide that the Company shall, to the fullest extent permitted by the NRS, as now or hereafter in effect, indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the Company, by reason of the fact that he is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (i) is not liable pursuant to NRS Section 78.138; or (ii) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

 

II-2

 

 

Item 7. Exemption from Registration Claimed.

 

Not applicable.

 

Item 8. Exhibits.

 

Exhibit Number	 	Description
5.1	 	Opinion of The Crone Law Group regarding validity of securities with consent to use
10.1	 	2022 Equity Incentive Plan
23.1	 	Consent of Kreit & Chiu CPA LLP
24.1	 	Power of Attorney
107	 	Filing Fee Table

 

Item 9. Undertakings.

 

A. The undersigned registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii)  To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

 

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

II-3

 

 

(4) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

B. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

II-4

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and authorized this registration statement to be signed on its behalf by the undersigned, in the state of Nevada, on June 20, 2025.

 

Inspire Veterinary Partners, Inc.		 
 	 	 
By:	/s/ Kimball Carr	 
 	Kimball Carr	 
 	Chief Executive Officer and Chairman	 
 	(Principal Executive Officer and Principal Financial and Accounting Officer)	 

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Keeler as his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or of their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates stated.

 

/s/ Kimball Carr	 	Chair, President and Chief Executive Officer	 	June 20, 2025
Kimball Carr	 	(Principal Executive Officer)	 	 
 	 	 	 	 
/s/ Richard Frank	 	Chief Financial Officer, Director	 	June 20, 2025
Richard Frank	 	(Principal Financial Officer)	 	 
 	 	 	 	 
/s/ Larry Alexander	 	Director	 	June 20, 2025
Larry Alexander	 	 	 	 
 	 	 	 	 
/s/ Charles Stith Keiser	 	Director	 	June 20, 2025
Charles Stith Keiser	 	 	 	 
 	 	 	 	 
/s/ Phillip Balatsos	 	Director	 	June 20, 2025
Phillip Balatsos	 	 	 	 
 	 	 	 	 
/s/ Anne Murphy	 	Director	 	June 20, 2025
Anne Murphy	 	 	 	 
 	 	 	 	 
/s/ Erinn Thomas-Mackey, DMV	 	Director	 	June 20, 2025
Erinn Thomas-Mackey, DMV	 	 	 	 
 	 	 	 	 
/s/ Timothy Watters	 	Director	 	June 20, 2025
Timothy Watters	 	 	 	 

 

II-5